---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-006548"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2025-04-29T23:59:59+00:00"
generated_at: "2026-05-23T04:19:30.026696+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# FDA approves Abeona's ZEVASKYN, first cell-based gene therapy for RDEB

## Summary
- 81% of ZEVASKYN-treated wounds achieved ≥50% healing at 6 months vs 16% control (P<0.0001) in Phase 3 VIITAL study.
- Rare Pediatric Disease Priority Review Voucher granted; company plans to monetize the PRV.
- ZEVASKYN available through Qualified Treatment Centers starting 3Q 2025; Abeona Assist support program launched.
- CEO cites pivotal moment for RDEB community; single surgical application aims for long-term wound healing and pain reduction.

## SEC filing metadata
- accession: 0001641172-25-006548
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2025-04-29T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000164117225006548/0001641172-25-006548-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000164117225006548/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-006548
- JSON: https://secwatch.observer/filing/0001641172-25-006548.json
- Plain text: https://secwatch.observer/filing/0001641172-25-006548.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.